Newsbenzinga
Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…